Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 1075-1083, 2007. First published April 19, 2007; 10.1373/clinchem.2006.075929
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.075929v1
53/6/1075    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by März, W.
Right arrow Articles by Boehm, B. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by März, W.
Right arrow Articles by Boehm, B. O.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1075-1083.)
© 2007 American Association for Clinical Chemistry, Inc.


Proteomics and Protein Markers

N-Terminal Pro-B-Type Natriuretic Peptide Predicts Total and Cardiovascular Mortality in Individuals with or without Stable Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study

Winfried März1,a, Beate Tiran2, Ursula Seelhorst3, Britta Wellnitz3, Johann Bauersachs4, Bernhard R. Winkelmann5 and Bernhard O. Boehm6

1 Synlab Center of Laboratory Diagnostics, Heidelberg, Germany.
2 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
3 Ludwigshafen Risk and Cardiovascular Health Study gGmbH, Freiburg, Germany.
4 Division of Cardiology, Department of Medicine, University of Würzburg, Würzburg, Germany.
5 Cardiology Group, Frankfurt-Sachsenhausen, Germany.
6 Division of Endocrinology, Department of Medicine, University Hospital, Ulm, Germany.

aAddress correspondence to this author at: Synlab Center of Laboratory Diagnostics Heidelberg, PO Box 10 47 80, D-69037 Heidelberg, Germany. Fax 49-6221-793-111; e-mail maerz{at}synlab.de.

Background: Measurement of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) measurement can be used to predict mortality in patients with acute coronary syndromes. Information on the value of NT-pro-BNP in clinically stable persons scheduled for angiography is limited.

Methods: We used Cox proportional hazards regression to examine the effect of NT-pro-BNP on total and cardiovascular mortality in 1135 with and 506 individuals without stable coronary artery disease (CAD).

Results: NT-pro-BNP was associated with New York Heart Association functional class, left ventricular (LV) systolic function, and LV end-diastolic pressure. NT-pro-BNP was positively related to age, female sex, hypertension, and former and current smoking and negatively related to body mass index and glomerular filtration rate. During a median follow-up of 5.45 years, NT-pro-BNP concentrations of 100–399, 400-1999, or ≥2000 ng/L resulted in unadjusted hazard ratios (95% CI) for all-cause death of 3.2 (1.8–5.6), 6.63 (3.8–11.6), and 16.5 (9.2–29.8), respectively, compared with concentrations <100 ng/L. Hazard ratios (CI) for death from cardiovascular causes were 3.8 (1.8–8.2), 9. 3 (4.4–19.5), and 22.2 (10.2–48.4). NT-pro-BNP remained predictive of total and cardiovascular mortality after accounting for age, sex, diabetes mellitus, body mass index, smoking, hypertension, dyslipidemia, glomerular filtration rate, presence or absence of CAD on angiography, cardiovascular medication, revascularization at baseline, clinical signs of heart failure, LV systolic function, and C-reactive protein.

Conclusions: NT-pro-BNP is predictive of all-cause and cardiovascular mortality in individuals with or without stable angiographic CAD independently of other cardiovascular risk factors, coronary atherosclerosis, and cardiac function.




The following articles in journals at HighWire Press have cited this article:


Home page
Eur Heart JHome page
K. Winkler, C. Wanner, C. Drechsler, J. Lilienthal, W. Marz, V. Krane, and for the German Diabetes and Dialysis Study Investi
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients
Eur. Heart J., September 1, 2008; 29(17): 2092 - 2099.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
K. Winkler, M. M. Hoffmann, U. Seelhorst, B. Wellnitz, B. O. Boehm, B. R. Winkelmann, W. Marz, and H. Scharnagl
Apolipoprotein A-II Is a Negative Risk Indicator for Cardiovascular and Total Mortality: Findings from the Ludwigshafen Risk and Cardiovascular Health Study
Clin. Chem., August 1, 2008; 54(8): 1405 - 1406.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.